Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Issue 2 (13th January 2020)

• Record Type: Journal Article
• Authors: Hoover, Paul; Der, Evan; Berthier, Celine C.; Arazi, Arnon; Lederer, James A.; James, Judith A.; Buyon, Jill; Petri, Michelle; Belmont, H. Michael; Izmirly, Peter; Wofsy, David; Hacohen, Nir; Diamond, Betty; Putterman, Chaim; Davidson, Anne
• Is Part Of: Arthritis care & research. Volume 72:Issue 2(2020)
• Page Start: 233
• Page End: 242
• Publication Date: 2020-01-13
• Subjects: Arthritis -- Periodicals; Rheumatism -- Periodicals; 616.72
• DOI: 10.1002/acr.24066
• Languages: English
• ISSNs: 2151-464X

Abstract

Abstract : The Accelerating Medicines Partnership (AMP) Lupus Network was established as a partnership between the National Institutes of Health, pharmaceutical companies, nonprofit stakeholders, and lupus investigators across multiple academic centers to apply high‐throughput technologies to the analysis of renal tissue, urine, and blood from patients with lupus nephritis (LN). The AMP network provides publicly accessible data to the community with the goal of generating new scientific hypotheses and improving diagnostic and therapeutic tools so as to improve disease outcomes. We present here a description of the structure of the AMP Lupus Network and a summary of the preliminary results from the phase 1 studies. The successful completion of phase 1 sets the stage for analysis of a large cohort of LN samples in phase 2 and provides a model for establishing similar discovery cohorts.